Amarantus Bioscience Holdings Inc (AMBS)

[joboggi]

The key is the sen, for research. Period. You don't want people in your study who do not have the disease. That lympro can add anything to the process remains to be seen.

and claiming a difference between version one and 2 based on 30 people so far is unwise.

AND assuming that a team would get two tests instead of one is ludicrous.

There is nothing supporting the use of Lympro WIDELY in research published to date, and there is no chance that it will be used to screen folks who are not in research.

saying it will happen will not make it happen. It is like saying that Nanosomix since it does not have what is considered a guru, will not have a good test. Indeed their test serum p tau, is at least two years ahead of AMBS.